Seamus O’Reilly, Professor at Cancer Trials Ireland, shared a post on LinkedIn:
“The future of ERBB2-positive breast cancer treatment is not simply escalation or de-escalation. It is adaptive treatment: the right intensity, at the right time, for the right patient.”
Hugely insightful article in JAMA Oncology by Naoto Ueno on the nuances for the ctDNA era on the ‘ need for the oncology community to generate strong evidence to reduce treatment without shifting uncertainty for patients’ and the relevance of such studies for patient centered care.”
Title: Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer
Author: Naoto T. Ueno
Read the article here.
Other articles about Breast Cancer on OncoDaily.